A delay-of-reward paradigm was used to assess impulsivity in rats. Previous research with
this paradigm has found that normally occurring impulsivity scores predict magnitude of …

Purpose To date there has not been an extensive analysis of the outcomes of biomarker use
in oncology. Methods Data were pooled across four indications in oncology drawing upon …

Introduction: This study analyzed the risk of clinical trial failure during non–small-cell lung
cancer (NSCLC) drug development between 1998 and January 2012. We also looked for …

We determined the success rate of new drug approval by the US FDA in two breast cancer
indications, one of which used a biomarker. This allowed us to assess if biomarkers improved …

The present study examined the role of the somatosensory cortex in the plasticity of thalamic
sensory maps. Thalamic plasticity was induced by the disruption of hindlimb input by …

This study analyzed the risk of clinical trial failure for leukemia drug development between
January 1999 and January 2020. The specific leukemia subtypes of interest were acute …

Objective. We conducted a systematic review to determine the risk of drug failure in clinical
testing with patients with moderate to severe rheumatoid arthritis (RA). Methods. Therapies …

Background The purpose of this study was to explore the effects biomarkers have on the
duration and speed of clinical trials in oncology. Materials and Methods Clinical trial data was …

Given the high morbidity and mortality associated with metastatic melanoma, considerable
attention has been paid to identifying potential therapies. Until recently, few therapies have …

e17804 Background: Despite many recent successes in oncology, a large number of drugs
still fail during clinical trial testing. It is widely believed that biomarkers are an important tool …